Archean Chemical Industries Limited sees a credit rating action

CRISIL’s downgrade was driven by a sharp weakening in debt protection, not by a reported FY26 debt-to-EBITDA figure alone. The rationale showed CRISIL-adjusted debt-to-net worth rising from 0.10x in FY25 to 0.26x in FY26, while interest coverage fell from 41.38x to 10.07x. These were accompanied by a PAT-margin decline from 15.6% to 9.7%. ^[1]

The quarterly trend supports the credit concern: Q1 FY27 total debt was Rs 466.38 Crores, up from Rs 178.06 Crores a year earlier, while EBITDA declined from Rs 86.33 Crores to Rs 72.87 Crores. ^{[10] [11] [12] [13]} Consequently, Q1 net debt/EBITDA rose from 1.59x to 5.83x, even as the interest-coverage ratio declined from 16.05x to 13.37x year on year. ^{[14] [7] [15] [4]}

Bottom line: the most direct alignment is the combination of substantially higher debt, weaker EBITDA and lower interest coverage. Q1 FY27’s 5.83x net debt/EBITDA is above CRISIL’s stated 4.0–4.25x downside reference, while the 13.37x quarterly interest coverage masks a weaker 6.16x TTM position. The comparison is directional because CRISIL uses adjusted annual metrics, whereas the quarterly results report company-level accounting ratios.

The incremental rated debt capacity was Rs 1,266 Crores, calculated as the revised Rs 1,531 Crores less the existing Rs 265 Crores ^[16].

The enhanced facility schedule breaks down as:

• Bromine-derivative capex: Rs 1,050 Crores, comprising proposed term loans of Rs 1,000 Crores and Rs 50 Crores ^[17].
• Short-term working capital: Rs 67 Crores, comprising proposed fund-based limits of Rs 22 Crores and Rs 45 Crores ^[17].

Thus, the specifically identified new-purpose facilities total Rs 1,117 Crores. The remaining Rs 149 Crores of the Rs 1,266-Crore increase reflects the higher amount assigned to existing facilities in the revised rating structure; the annexure does not separately identify its end-use ^[17]. These are rated facility limits, not evidence that the full amount had already been drawn.

Verdict: ACI has moved from a historically low-leverage balance sheet to a moderately levered, more execution-sensitive profile. Its latest reported debt-to-equity ratio of 0.24x is above FCL, Balaji Amines and Foseco, broadly similar to Laxmi Organic, and well below Neogen. However, ACI’s net debt/EBITDA of 5.83x is more stretched than every peer except Neogen, while its 13.37x interest coverage remains adequate but is materially weaker than most peers.

ACI: leverage and debt-service progression

ACI’s debt-to-equity ratio has therefore risen by 0.21x from FY24 to Q1 FY27, while reported total debt increased from Rs 59.55 Crores in FY24 to Rs 466.38 Crores in FY26 and Q1 FY27 ^{[27] [10]}. Interest coverage recovered from the FY26 low of 6.71x to 13.37x in Q1 FY27, but remains far below the 51.49x recorded in FY24.

The CRISIL-adjusted view is also weaker than history: adjusted debt/adjusted net worth increased from 0.10x in FY25 to 0.26x in FY26, while adjusted interest coverage declined from 41.38x to 10.07x ^[1]. The difference between CRISIL’s 10.07x and the KPI-reported 6.71x for FY26 reflects different adjustment and metric definitions, so they should not be treated as contradictory measures.

Q1 FY27 peer comparison

The comparison shows three points:

• On equity leverage: ACI’s 0.24x is not extreme relative to Neogen’s 1.63x, but it is substantially above Fineotex’s 0.01x, Balaji’s 0.07x and Foseco’s zero ratio. It is only marginally below Laxmi Organic’s 0.27x.
• On debt-servicing capacity: ACI’s 13.37x interest coverage is stronger than Neogen’s 2.50x, but materially weaker than Laxmi Organic’s 27.39x and the much higher coverage reported by Fineotex, Balaji Amines and Foseco.
• On cash-flow leverage: ACI’s 5.83x net debt/EBITDA is more demanding than Laxmi Organic’s 4.08x and far above the low or negative ratios of Fineotex, Balaji and Foseco. Only Neogen is materially more stretched at 25.44x.

What the enhancement changes

On 22 October 2026, CRISIL enhanced ACI’s rated long-term bank facilities from Rs 265 Crores to Rs 1,531 Crores, while downgrading the rating from CRISIL A/Negative to CRISIL A-/Stable ^[16]. The enhancement is a substantially larger financing envelope; it should not be substituted for reported drawn debt in the debt-to-equity calculation. The latest reported Q1 FY27 total debt remains Rs 466.38 Crores ^[10].

The rating action matters because CRISIL expects project-related debt and capital expenditure to pressure debt-protection metrics during implementation; projected capital expenditure was indicated at approximately Rs 1,300-1,500 Crores by FY27 ^[43]. CRISIL also identifies sustained net debt/EBITDA of 4.0-4.25x as a downside sensitivity factor ^[1]. ACI’s Q1 FY27 reported 5.83x is above that range, although the quarterly KPI ratio is not directly equivalent to CRISIL’s adjusted, sustained metric.

Overall, ACI remains better positioned than Neogen on interest coverage and equity leverage, but its post-enhancement trajectory is materially less conservative than the low-debt peer group. The key uncertainty is not the current 0.24x D/E alone; it is whether incremental borrowing for the project can be matched by operating cash-flow growth before net debt/EBITDA remains elevated for a sustained period.